Arch Therapeutics, Inc. (ARTH)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Terrence W. Norchi M.D. | Co-Founder, Chairman, President & CEO | 450.5k | -- | 1965 |
Mr. Michael S. Abrams | CFO & Treasurer | 325k | -- | 1970 |
Dr. Rutledge Ellis-Behnke Ph.D. | Co-Founder & Scientific Advisor | -- | -- | -- |
Mr. Shawn Carlson | Vice President of Sales | -- | -- | -- |
Arch Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 8
Description
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.
Corporate Governance
Recent Events
- Apr 03, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 18, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 01, 202410-K/A: Periodic Financial ReportsSee Full Filing
- Feb 20, 202410-Q: Periodic Financial ReportsSee Full Filing
- Feb 15, 202410-K: Periodic Financial ReportsSee Full Filing